← Eichor
Condition: Advanced Biliary Tract Cancer Btc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Biliary Tract Cancer Btc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT07151118Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
Phase N/A · 1 location(s) · CHA University · NCT07142226AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Phase 2 · 1 location(s) · Columbia University · NCT07433673A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 · 6 location(s) · SEED Therapeutics, Inc. · NCT07197554Cosiporfin Sodium for Injection Photodynamic Therapy
Phase 2 · 1 location(s) · Shanghai Guangsheng Biopharmaceutical Co., Ltd · NCT07398339Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT06893380Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07614061GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）
Phase N/A · 1 location(s) · Fudan University · NCT06988592Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07159204Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Yuhan Corporation · NCT06975410Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Phase 3 · 21 location(s) · Taiho Pharmaceutical Co., Ltd. · NCT07710885A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Bilio
Phase N/A · 1 location(s) · Tongji Hospital · NCT07326137D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Phase 3 · 3 location(s) · InnoPharmax Inc. · NCT06622057Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in
Phase 3 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07229625Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Phase 3 · 270 location(s) · AstraZeneca · NCT06467357Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Phase N/A · 1 location(s) · CHA University · NCT06648057Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced G
Phase 1/Phase 2 · 11 location(s) · Phanes Therapeutics · NCT05482893A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Parti
Phase 2 · 54 location(s) · Bayer · NCT06760819A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Ph
Phase 3 · 18 location(s) · J-Pharma Co., Ltd. · NCT07265674
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.